181 related articles for article (PubMed ID: 31982285)
1. Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions.
Kato ET; Das SR; McGuire DK
Trends Cardiovasc Med; 2021 Feb; 31(2):101-108. PubMed ID: 31982285
[TBL] [Abstract][Full Text] [Related]
2. Current perspectives on cardiovascular outcome trials in diabetes.
Schnell O; Rydén L; Standl E; Ceriello A;
Cardiovasc Diabetol; 2016 Oct; 15(1):139. PubMed ID: 27716274
[TBL] [Abstract][Full Text] [Related]
3. Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight.
Coch RW; Green JB
Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):767-72. PubMed ID: 27378397
[TBL] [Abstract][Full Text] [Related]
4. Drugs for type 2 diabetes mellitus: the imperative for cardiovascular outcome assessment.
Gore MO; McGuire DK
Diab Vasc Dis Res; 2012 Apr; 9(2):85-8. PubMed ID: 22496441
[No Abstract] [Full Text] [Related]
5. Cardiovascular trials and diabetes treatments: a regulatory maze.
Matthews DR
Diab Vasc Dis Res; 2012 Apr; 9(2):83-4. PubMed ID: 22419242
[No Abstract] [Full Text] [Related]
6. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
Bonadonna RC; Borghi C; Consoli A; Volpe M
Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs?
Low Wang CC; Everett BM; Burman KD; Wilson PWF
Circulation; 2019 Apr; 139(14):1741-1743. PubMed ID: 30933621
[No Abstract] [Full Text] [Related]
8. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
Verma S; Leiter LA; Mazer CD; Bain SC; Buse J; Marso S; Nauck M; Zinman B; Bosch-Traberg H; Rasmussen S; Michelsen MM; Bhatt DL
Circulation; 2018 Oct; 138(15):1605-1607. PubMed ID: 30354517
[No Abstract] [Full Text] [Related]
9. Cardiovascular Safety Trials of Antidiabetic Therapies to Treat Type 2 Diabetes: Perhaps Asking the Wrong Question?
Psaty BM; Fleming TR
Am J Hypertens; 2019 Sep; 32(10):927-929. PubMed ID: 31175821
[No Abstract] [Full Text] [Related]
10. [Not Available].
Steurer J
Praxis (Bern 1994); 2016 Sep; 105(20):1221-1222. PubMed ID: 27705192
[No Abstract] [Full Text] [Related]
11. Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.
Alfayez OM; Almohammed OA; Alkhezi OS; Almutairi AR; Al Yami MS
Cardiovasc Diabetol; 2020 Jun; 19(1):96. PubMed ID: 32571416
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Safety of Antihyperglycemic Agents: "Do Good or Do No Harm".
Manolis AA; Manolis TA; Manolis AS
Drugs; 2018 Oct; 78(15):1567-1592. PubMed ID: 30251174
[TBL] [Abstract][Full Text] [Related]
13. What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?
Lovre D; Htun W; Carrion C; Fonseca VA
Curr Diab Rep; 2016 Oct; 16(10):94. PubMed ID: 27541296
[TBL] [Abstract][Full Text] [Related]
14. Is glycemic control a quinidine-like intervention?
Bloomgarden ZT
J Diabetes; 2014 Sep; 6(5):387-8. PubMed ID: 24842383
[No Abstract] [Full Text] [Related]
15. Cardiovascular effects of some antidiabetic drugs.
Med Lett Drugs Ther; 2017 Aug; 59(1527):136-138. PubMed ID: 28787745
[No Abstract] [Full Text] [Related]
16. Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.
Standl E; Schnell O; McGuire DK
Circ Res; 2016 May; 118(11):1830-43. PubMed ID: 27230644
[TBL] [Abstract][Full Text] [Related]
17. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Sharma A; Pagidipati NJ; Califf RM; McGuire DK; Green JB; Demets D; George JT; Gerstein HC; Hobbs T; Holman RR; Lawson FC; Leiter LA; Pfeffer MA; Reusch J; Riesmeyer JS; Roe MT; Rosenberg Y; Temple R; Wiviott S; McMurray J; Granger C
Circulation; 2020 Mar; 141(10):843-862. PubMed ID: 31992065
[TBL] [Abstract][Full Text] [Related]
18. Type 2 diabetes mellitus and cardiovascular disease: focus on the effect of antihyperglycemic treatments on cardiovascular outcomes.
Choxi R; Roy S; Stamatouli A; Mayer SB; Jovin IS
Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):187-199. PubMed ID: 32306789
[No Abstract] [Full Text] [Related]
19. Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes.
Chilton RJ; Dungan KM; Shubrook JH; Umpierrez GE
Prim Care Diabetes; 2020 Jun; 14(3):193-212. PubMed ID: 31704161
[TBL] [Abstract][Full Text] [Related]
20. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.
Sposito AC; Berwanger O; de Carvalho LSF; Saraiva JFK
Cardiovasc Diabetol; 2018 Dec; 17(1):157. PubMed ID: 30545359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
